Jennifer L Hay, Erica H Lee, Stephanie N Christian, Elizabeth Schofield, Jada G Hamilton, Ciyu Yang, Bobak Hedayati, Keimya Sadeghi, Mark E Robson, Allan Halpern, Liying Zhang, Irene Orlow
Public access to genetic information is increasing, and community dermatologists may progressively encounter patients interested in genetic testing for melanoma risk. Clarifying potential utility will help plan for this inevitability. We determined interest and uptake of genetic risk feedback based on melanocortin receptor gene ( MC1R ) variants, immediate (two weeks) responses to risk feedback, and test utility at three months in patients (age ≥ 18, with a history of nonmelanoma skin cancer). Participants ( N = 50) completed a baseline survey and were invited to consider MC1R testing via the study website...
2022: Journal of Skin Cancer